Anthropic CEO says AI could cure most major diseases within next decade

Patients and biotech developers stand to gain substantially if computational models can independently unlock new genetic tools. Anthropic initially announced that its AI model Claude discovered a novel enzyme system with CRISPR-like repeats, marking an operational milestone for its biology lab. Al Jazeera and The Verge documented the company's direct comparison between this newly identified system and established Crispr mechanisms, while TechCrunch framed the internal biolab finding as a major biological development.

Later coverage extended the scope from a single biological mechanism to broad therapeutic promises. Fox Business reported that Anthropic's CEO contends AI could cure most major diseases within the next decade. This introduces a noticeable contrast in scale: while technical accounts focus strictly on Claude's identification of CRISPR-like repeats in a laboratory setting, executive statements escalate the discovery into an imminent decade-long timeline for curing major global diseases.

Today, the claims from Anthropic pair a specific laboratory finding with vast medical projections. Claude is formally credited with discovering a CRISPR-like enzyme system through the company's biolab, while its chief executive stakes the next ten years on artificial intelligence resolving the majority of major human illnesses.